• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The 'Generic Handbook 2007' Contains Detailed Product Analysis on Over 200 Top Generic Drugs, and Profiles of the Top 75 US Generic Drug Companies Including Financial Data and Contact Information

Posted on: Tuesday, 20 February 2007, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c50637) has announced the addition of 'Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition' to their offering.

The 'Generic Handbook' provides comprehensive analysis and business intelligence on the generic drug industry in the United States. Editorial coverage includes: analysis of the legal and regulatory issues at play within the US market, a section devoted to the political and regulatory environment, analysis of the customers and distribution chain, detailed product analysis on over 200 top generic drugs, and profiles of the top 75 US generic drug companies (including financial data and contact information).

Regulatory Section:

FDA structure and policies

Administrative actions and trends

Hatch-Waxman trends in case law

Paragraph IV challenges and success rates

Market Section:

Highlights and recent news

Opportunity assessment for products losing patent 2006 - 2011

Sales and growth rates by product (Top 200)

Top 20 therapeutic categories

Total category sales

Total patented sales within category

Percent market-share within therapeutic category

Share by company within therapeutic category

Company Section:

General contact information

Senior Executives

Description of company history, areas of therapeutic focus, etc.

Number/Type of Drug Master Files (DMF's)

Ownership structure (public vs. private)

Sales figures for previous 4-year period

Information about company strategy (e.g. pursing authorized generic deals with big pharma vs. agressively pursing patent litigation

Financial data (public companies)

Chapter Outline:

Chapter 1: Introduction to GenericHandbook

Chapter 2: Context of Generic Drugs in the United States

Chapter 3: Regulatory & Legal Environment

Chapter 4: Political, Regulatory, & Legal Developments

Chapter 5: Customers & The Distribution Chain

Chapter 6: The United States Generic Drug Market

Chapter 7: Major Issues Facing the Generic Industry

Chapter 9: Products

Chapter 9: Companies

Companies Mentioned:

Abbott Laboratories

Abraxis Pharmaceutical Products

Abrika Pharmaceuticals

Actavis

Akyma Pharmaceuticals

American Regent

Amide Pharmaceutical

Andrx Pharma

Apotex

Armstrong Pharmaceuticals

Aurobindo Pharma

Barr Pharmaceuticals

Bausch & Lomb

Baxter International, Inc

Bedford Laboratories

Bertek (Mylan Bertek)

Boca Pharmacal

Breckenridge Pharmaceutical

Caraco Pharmaceutical

Cypress Pharmaceutical Inc

DAVA Pharmaceuticals

Dey Laboratories

Dr Reddy's Laboratories

Endo Pharmaceuticals

Ethex

Falcon Pharmaceuticals

Forest Laboratories (Inwood)

Fougera

G&W Laboratories

Glades Pharmaceuticals

Glenmark Pharmaceuticals

Global Pharmaceuticals

Greenstone

Hercon Laboratories

Hi-Tech Pharmacal Co

Hospira

Interpharm

IVAX

Kremers Urban

Lannett Co

Lupin

Major Pharmaceuticals

Mallinckrodt

Midlothian Labs

Mikart

Morton Grove Pharmaceuticals

Mutual Pharmaceutical Co United Research Labs/Mutual

Mylan Laboratories

Paddock Laboratories

Par Pharmaceutical

Perrigo

Pharmaderm

Pliva

Prasco Laboratories

Purepac

Ranbaxy

Rising Pharmaceutical Int

Roxane

Rugby

RxElite

Sandoz

Sicor

Stada

Taro Pharmaceuticals USA

Teva USA

Three Rivers Pharmaceuticals

Triax Pharmaceuticals

Upsher-Smith

Warrick Pharmaceuticals

Watson Pharmaceuticals

Wockhardt USA

Xanodyne

Xttrium Laboratories

Zydus Pharmaceutical

For more information visit http://www.researchandmarkets.com/reports/c50637

Source: Business Wire

More News in this Category